Menu
Back to User profile » Professor Xiaochun Zhang
Papers published by Professor Xiaochun Zhang:
The Efficacy and Safety of PD-1 Inhibitors Combined with Nab-Paclitaxel Plus Gemcitabine versus Nab-Paclitaxel Plus Gemcitabine in the First-Line Treatment of Advanced Pancreatic Cancer: A Retrospective Monocentric Study
Zhang F, Wang Y, Yang F, Zhang Y, Jiang M, Zhang X
Cancer Management and Research 2022, 14:535-546
Published Date: 9 February 2022
Antiangiogenesis Combined with Immunotherapy to Treat Advanced Small-Cell Carcinoma of the Esophagus Resistant to Chemotherapy: According to the Guidance of Next-Generation Sequencing
Jiang M, Zhang X
OncoTargets and Therapy 2021, 14:1613-1621
Published Date: 2 March 2021
A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies
Qu J, Wang L, Jiang M, Zhao D, Wang Y, Zhang F, Li J, Zhang X
Cancer Management and Research 2020, 12:6493-6509
Published Date: 28 July 2020
Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
Hou H, Qin K, Liang Y, Zhang C, Liu D, Jiang H, Liu K, Zhu J, Lv H, Li T, Zhang X
Cancer Management and Research 2019, 11:5665-5675
Published Date: 21 June 2019
The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
Hou H, Sun D, Liu K, Jiang M, Liu D, Zhu J, Zhou N, Cong J, Zhang X
Cancer Management and Research 2019, 11:4109-4118
Published Date: 7 May 2019
The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
Sun D, Hou H, Zhang C, Zhang X
OncoTargets and Therapy 2018, 11:6539-6554
Published Date: 5 October 2018
Progress in the treatment of solid tumors with apatinib: a systematic review
Zhao D, Hou H, Zhang X
OncoTargets and Therapy 2018, 11:4137-4147
Published Date: 19 July 2018